Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Hepatitis B, Chronic

  • SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
    Recruiting


  • ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).
    Completed


  • A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
    Completed


  • Prevention of Recurrent Hepatitis B After Liver Transplantation
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
    Completed


  • A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
    Terminated


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement